Video

Q&A with Brian Bolwell: Efficacy of Immunologic and Genomic Therapies

Author(s):

Brian Bolwell, MD, Cleveland Clinic, discussed how all the information they're finding out about myeloid malignancies is very important, but also complex so making broad statements is challenging.

Brian Bolwell, MD, Cleveland Clinic, discussed how all the information they're finding out about myeloid malignancies is very important, but also complex so making broad statements is challenging.

Regarding progress, Bolwell stated, "As my role as director of the Cleveland Clinic, we're very concerned about healthcare economics and showing value, and ASH is at the forefront of trying to publicize the challenge of the ongoing challenge of the ongoing cost of targeted therapies."

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.